← All trials
NCT04560881
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2020
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- Sep 23, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorio Elea S.A.C.I.F. y A.Lead sponsor
- China National Biotec Group Co., LtdCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
- Fundacion HuespedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.